Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Precision proteomics companies race to commercialize blood-based disease detection

Precision proteomics companies race to commercialize blood-based disease detection

New Capabilities

Alamar Biosciences surges 29% on Nasdaq debut, signaling renewed investor appetite for protein diagnostics after years of hype and disappointment

April 17th, 2026: Alamar prices upsized IPO at $17 per share

Overview

Alamar Biosciences raised $191 million in its initial public offering on April 17, 2026 (nearly double the $100 million it originally planned) after investor demand exceeded available shares by more than tenfold. Shares priced at $17, opened at $22.60, and closed at $22.00, a 29% first-day gain that gave the company a market capitalization of roughly $1.53 billion. The Fremont, California company develops technology that detects proteins in blood at concentrations so low that conventional tests miss them entirely, potentially catching diseases years earlier than current methods allow. CEO and founder Yuling Luo told Reuters the company plans to use the proceeds to expand into cancer, cardiology, and other major disease areas. The company reported $74.2 million in revenue for fiscal year 2025 (nearly triple the year prior), creating a baseline for investors to measure future commercial growth.

The historic biotech listings day saw obesity-drug developer Kailera Therapeutics raise $625 million in its April 17 IPO (the largest since Moderna's $600 million raise in 2018), surging 63% on its first day. Analysts cited both offerings as evidence investor appetite for life sciences listings had returned, a reversal from 2021–2023 when three protein-analysis firms' valuations collapsed. Thermo Fisher Scientific's $3.1 billion acquisition of Olink in early 2024 and breakthroughs in blood-based Alzheimer's testing proved that protein detection could solve real clinical problems.

Why it matters

Blood tests that detect diseases before symptoms appear could shift medicine from treatment to prevention — if the technology proves out at scale.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict

Key Indicators

$191M
IPO proceeds
Nearly double the originally planned $100 million raise
10x
Oversubscription ratio
Investor demand exceeded available shares by more than tenfold
$22.00
First-day close
Shares closed 29.4% above the $17 IPO price on April 17, giving Alamar a ~$1.53B market cap
$74.2M
FY2025 revenue
Full-year 2025 revenue, nearly triple the prior year — the baseline public investors will measure growth against
$3.1B
Olink acquisition price
Thermo Fisher's early 2024 purchase of competitor Olink set the valuation benchmark for the sector

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

January 2020 April 2026

12 events Latest: April 17th, 2026 · 1 month ago Showing 8 of 12
Tap a bar to jump to that date
  1. Alamar prices upsized IPO at $17 per share

    Latest Corporate

    Alamar Biosciences begins trading on Nasdaq under ticker ALMR after pricing 11.25 million shares at $17 each, raising $191 million — nearly double the originally planned $100 million — with more than 10x oversubscription.

  2. Kailera Therapeutics prices IPO the same day as Alamar, signaling biotech window reopening

    Market

    Obesity-drug developer Kailera Therapeutics launched its IPO alongside Alamar on April 17, 2026, with analysts citing both offerings as evidence that the biotech listings window had materially reopened after a multi-year drought.

  3. ALMR surges 29% on first day of Nasdaq trading

    Market

    Alamar Biosciences shares opened at $22.60 and closed at $22.00, a 29.4% gain above the $17 IPO price, giving the company a market capitalization of approximately $1.53 billion on its first trading day.

  4. Kailera Therapeutics raises $625M in largest biotech IPO since Moderna (2018)

    Market

    Obesity-drug developer Kailera Therapeutics raised $625 million and surged 63% on its Nasdaq debut (ticker: KLRA), making April 17, 2026 one of the most significant single days for biotech public listings in years.

  5. Blood-based Alzheimer's tests reach clinical validation

    Scientific

    Multiple protein-based blood tests for Alzheimer's disease achieve over 90% accuracy, demonstrating that protein detection can solve urgent clinical problems and driving demand for proteomics platforms.

  6. Tempus AI IPOs at $6.1B valuation

    Market

    Artificial intelligence-driven precision medicine company Tempus raises $410 million in its IPO, signaling renewed appetite for diagnostics companies on public markets.

  7. SomaLogic merges with Standard BioTools

    Market

    After its stock declined sharply from its SPAC debut, SomaLogic merges with Standard BioTools at a fraction of its original valuation.

  8. FDA finalizes rule on laboratory-developed tests

    Regulatory

    The Food and Drug Administration issues a final rule phasing out enforcement discretion for laboratory-developed tests over four years, raising the regulatory bar for diagnostic companies.

  9. Thermo Fisher completes Olink deal

    Market

    The acquisition closes, giving Thermo Fisher a competing proteomics platform with global distribution and established pharma relationships.

  10. Thermo Fisher announces $3.1B Olink acquisition

    Market

    The world's largest life sciences tools company agrees to buy proteomics platform maker Olink for $3.1 billion in cash, validating the commercial potential of high-throughput protein detection.

  11. SomaLogic goes public via SPAC

    Market

    Proteomics competitor SomaLogic lists at a $1.2 billion valuation through a special-purpose acquisition company, part of a wave of pre-revenue life science SPACs.

  12. Alamar Biosciences founded

    Corporate

    Tae Man Kim and co-founders establish Alamar Biosciences in Fremont, California, to develop the NULISA ultra-sensitive protein detection technology.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 2021 - 2024

SomaLogic SPAC listing and decline (2021-2024)

SomaLogic, which developed the SomaScan aptamer-based proteomics platform capable of measuring over 7,000 proteins, went public through a special-purpose acquisition company at a $1.2 billion valuation in September 2021. The company had limited revenue and faced a steep path to profitability.

Then

The stock declined more than 80% from its SPAC listing price within two years as investors soured on pre-revenue life science companies.

Now

SomaLogic merged with Standard BioTools at a fraction of its original valuation, serving as a cautionary tale about taking proteomics platforms public before establishing commercial traction.

Why this matters now

Alamar's heavily oversubscribed IPO at nearly double the planned size suggests investors believe the company has learned from SomaLogic's mistakes — or that the market has fundamentally matured since 2021. Whether Alamar can avoid the same post-IPO decline will depend on converting research interest into recurring revenue.

October 2018

Guardant Health IPO and liquid biopsy commercialization (2018)

Guardant Health, which developed blood-based cancer detection tests using circulating tumor DNA rather than proteins, went public at a $2.3 billion valuation. The company had the Guardant360 test in clinical use and a clear regulatory strategy.

Then

The stock more than tripled within a year as Guardant demonstrated rapid revenue growth from its liquid biopsy tests.

Now

Guardant secured Food and Drug Administration approval for Guardant360 CDx as a companion diagnostic and expanded into early cancer detection with its Shield test, validating the path from research tool to approved clinical diagnostic.

Why this matters now

Guardant's trajectory illustrates the playbook Alamar may follow: establish the platform in research, build clinical evidence, then pursue regulatory approval for diagnostic use. The key difference is that Guardant detected DNA fragments while Alamar detects proteins — a complementary approach that could prove more sensitive for certain cancer types.

October 2023 - February 2024

Thermo Fisher acquires Olink Proteomics (2023-2024)

Thermo Fisher Scientific, the world's largest life sciences tools company with over $40 billion in annual revenue, acquired Swedish proteomics company Olink for $3.1 billion in an all-cash deal. Olink's Proximity Extension Assay technology could measure over 5,000 proteins from a single blood sample.

Then

The deal validated proteomics as a commercial category worthy of multi-billion-dollar investment by the industry's largest player.

Now

Thermo Fisher's global distribution network accelerated Olink's platform adoption but also created a dominant incumbent that smaller proteomics companies must compete against.

Why this matters now

This acquisition is the single most important event shaping Alamar's market opportunity. It proved that proteomics platforms command premium valuations, but it also installed a formidable competitor with unmatched distribution power. Alamar's success depends partly on whether the market is large enough for multiple platforms to thrive.

Sources

(13)